CFI-400437 

CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC₅₀ of 0.6 nM)^[1].

CFI-400437 is a potent inhibitor of MCF-7, MDA-MB-468 and MDA-MB231 cell growth^[1].
CFI-400437 inhibits Aurora A, Aurora B, KDR and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 µM, respectively, i.e. two orders of magnitude higher than its IC₅₀ of 0.6 nM against PLK4^[1].
CFI-400437 inhibits both AURKB and AURKC at concentrations <15 nM^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CFI-400437 (25 mg/kg, ip, once daily for 21 d) exhibits antitumor activity against MDA-MB-468 breast cancer mouse xenograft model^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

492.57

C₂₉H₂₈N₆O₂

1169211-37-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Radoslaw Laufer, et al. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem. 2013 Aug 8;56(15):6069-87.  [Content Brief]

  [2]. Amreena Suri, et al. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. Int J Mol Sci. 2019 Apr 29;20(9):2112.  [Content Brief]